22nd Century Group Inc Sells GVB Biopharma for $2.25 Million

Business by 2FIRSTS.ai
Nov.29.2023
22nd Century Group Inc Sells GVB Biopharma for $2.25 Million
US cigarette manufacturer, 22nd Century Group Inc, has sold its cannabis subsidiary, GVB Biopharma, for $2.25 million, exiting the industry after less than 18 months.

According to a report by Journalnow on November 29, American cigarette manufacturer 22nd Century Group Inc has announced the sale of its cannabis subsidiary, GVB Biopharma, for a sum of $2.25 million. This move signifies the company's formal exit from the cannabis industry, which proved to be a significant financial burden in less than a year and a half.

 

According to regulatory documents released on Monday, the purchaser of GVB is Specialty Acquisition Corp, a professional acquisition company based in Nevada.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Special Report| Vuse Gains as U.S. Cracks Down on Illegal Vapes, But a $590 Million China Export Shadow Looms
Special Report| Vuse Gains as U.S. Cracks Down on Illegal Vapes, But a $590 Million China Export Shadow Looms
The payoff is here: BAT’s Vuse has seized a rare regulatory vacuum to reverse its U.S. slide, capitalizing on a crackdown that seemingly compressed the illicit market to 54%. But the victory is fragile. A record $590 million export shock in October signals the gray market is striking back—pitting a fleeting compliance dividend against a massive inventory wall.
BAT
Dec.09
Philippines DTI Floats Blanket Ban on Open-Pod Vapes and E-Liquids, Seeks Public Input
Philippines DTI Floats Blanket Ban on Open-Pod Vapes and E-Liquids, Seeks Public Input
Philippines’ Department of Trade and Industry (DTI) is inviting stakeholder feedback on a draft Department Administrative Order (DAO) that would impose a blanket ban on open vape pods and e-liquids—covering use, manufacturing, importation, and distribution.
Jan.29 by 2FIRSTS.ai
Interpreting FDA’s on! PLUS Authorization: What the Agency’s Press Release Reveals About Its Nicotine Pouch Review Model
Interpreting FDA’s on! PLUS Authorization: What the Agency’s Press Release Reveals About Its Nicotine Pouch Review Model
The U.S. Food and Drug Administration has confirmed that six on! PLUS nicotine pouch products have received Marketing Granted Orders (MGO) through the PMTA pathway. The authorizations were completed under the agency’s nicotine pouch review pilot program in “record time,” with the FDA citing lower levels of harmful constituents while stressing that the decision applies only to the specified products and does not mean they are safe or FDA approved.
Regulations
Dec.20
PMI AI White Paper Warns of “Cognitive Atrophy” and Attention Erosion, Calls for Focus on Human Cognition’s Evolution
PMI AI White Paper Warns of “Cognitive Atrophy” and Attention Erosion, Calls for Focus on Human Cognition’s Evolution
Philip Morris International (PMI) has released a white paper calling for cross-sector dialogue on how AI may affect human cognitive abilities. The paper flags risks including “cognitive atrophy” and attention erosion, and warns of a widening cognitive divide and rising pressures on information verification and trust.
Jan.21 by 2FIRSTS.ai
Alabama SB9 advances: Senate committee clears bill to treat vaping like smoking in enclosed public places
Alabama SB9 advances: Senate committee clears bill to treat vaping like smoking in enclosed public places
Alabama’s Senate Bill 9 advanced after clearing the Senate Committee on Healthcare, moving to the full Alabama Senate for consideration. The proposal would update the state’s 2003 Clean Indoor Air Act by including e-cigarettes and other vaping devices under the same restrictions that apply to smoking in most enclosed public places.
Jan.22 by 2FIRSTS.ai
Wisconsin Lawmakers Revive Bill to Raise Legal Age for Tobacco and Vaping Purchases to 21
Wisconsin Lawmakers Revive Bill to Raise Legal Age for Tobacco and Vaping Purchases to 21
Wisconsin Senate Bill 524 (SB 524) has been reintroduced to raise the legal purchasing age for tobacco and electronic nicotine products from 18 to 21, aiming to eliminate the gap between state law and the federal “Tobacco 21” standard. Some retailers in Madison have already voluntarily adopted the 21-year age limit, while the American Lung Association is urging swift legislative action.
Dec.04 by 2FIRSTS.ai